


Claims

1. A compound or stereoisomer thereof having the structure of Formula (I)



Formula (I)

wherein:

R^1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C_1 - C_2 alkylene bridge or R^1 is a C-linked 5-8 membered fused bicyclic heterocycloalkyl containing 1-2 N heteroatoms,


wherein

said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is unsubstituted,


or said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is substituted with an R^7 and 0 to 3 substituents independently selected from R^5 ,

or said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is substituted with 1 to 3 substituents independently selected from R^5 ;


R^2 is $-C_1$ - C_6 alkyl;





R^4 is $-OH$, C_1 - C_6 alkoxy, $-LR^9$, $-NHS(O)_2R_{11}$, $-NHS(O)_2(CH_2)_mN_3$, $-NHS(=O)_2LR^9$,






R^5 is, C_1 - C_6 alkyl $-C(=O)R^{11}$, $-(CH_2)_mOH$, $-C(=O)(CH_2)_mOH$, $-C(=O)((CH_2)_mO)_nR^{12}$, or C_1 - C_6 alkyl substituted with $-CN$, or $-C(=O)NH_2$;




and L_2 is independently selected from a bond and L_1 ;



5



R^{10} is




each R^{11} is independently selected from C_1 - C_6 alkyl;

10

each R^{12} is independently selected from H and C_1 - C_6 alkyl;

R^{13} is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl,



each R^{19} is H or C_1 - C_6 alkyl;



15

each m is independently selected from 1, 2, 3, 4, 5, and 6;

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12,


or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R³ is




and R¹⁹ is H.

3. The compound of claim 1 or claim 2, wherein the compound is a compound having the structure of Formula (Ia):



Formula (Ia).

4. The compound of any one of claims 1 to 3, wherein the compound is a compound having the structure of Formula (Ib):



Formula (Ib).

5. The compound of any one of claims 1 to 4, wherein each L is L₁L₂- or L is -L₁-.
6. The compound of any one of claims 1 to 5, wherein:


R¹ is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C₁-C₂alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is substituted with an R⁷ and 0 to 3 substituents independently selected from R⁵.

7. The compound any one of claims 1 to 6, wherein:

R¹ is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C₁-C₂alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is substituted with an R⁷ and 0 to 3 substituents independently selected from R⁵,

and

R⁴ is -OH, C₁-C₆alkoxy, -NHS(O)₂(CH₂)_mN₃, -NHS(O)₂R₁₁ or





8. The compound any one of claims 1 to 7, wherein:




R^2 is $-C_1-C_6$ alkyl;


R^5 is C_1-C_6 alkyl, $-C(=O)R^{11}$, $-(CH_2)_mOH$, $-C(=O)(CH_2)_mOH$, or $-C(=O)((CH_2)_mO)_nR^{12}$;


R^7 is L_1R^9 ;

5 R^8 is H;

R^9 is , , $-N_3$, $-SH$, $-S(=O)_2(CH=CH_2)$, $-NR_{12}C(=O)CH_2Br$, -

$NR_{12}C(=O)CH_2I$, $-NHC(=O)CH_2Br$, $-NHC(=O)CH_2I$, $-ONH_2$, , , , or




;




10 R^{10} is

each R^{11} is independently selected from C_1-C_6 alkyl;


each R^{12} is independently selected from H and C_1-C_6 alkyl; and

R^{13} is tetrazolyl, , , or .


9. The compound of any one of claims 1 to 8, wherein R^1 is




15 10. The compound of any one of claims 1 to 8, wherein R^1 is



11. The compound of any one of claims 1 to 8, wherein R^1 is





12. The compound of any one of claims 1 to 8, wherein R^1 is

13. The compound of any one of claims 1 to 5, wherein:

R^1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C_1 - C_2 alkylene bridge, or R^1 is a C-linked 5-8 membered fused bicyclic heterocycloalkyl containing 1-2 N heteroatoms,

wherein

said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is unsubstituted,



or said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is substituted with 1 to 3 substituents independently selected from R^5 .

14. The compound of any one of claims 1 to 5, wherein:

R^1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C_1 - C_2 alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is unsubstituted or is substituted with 1 to 3 substituents independently selected from R^5 and R^6 .

15. The compound of any one of claims 1 to 5, wherein:

R^1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C_1 - C_2 alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is unsubstituted or is substituted with 1 to 3 substituents independently selected from R^5 and R^6 ;






16. The compound of any one of claims 1 to 5, or 15, wherein:



R^2 is $-C_1-C_6$ alkyl;


R^5 is C_1-C_6 alkyl, $-C(=O)R^{11}$, $-(CH_2)_mOH$, $-C(=O)(CH_2)_mOH$, or $-C(=O)((CH_2)_mO)_nR^{12}$;


5 R^8 is L_1R^9 ;

R^9 is , , $-N_3$, $-SH$, $-S(=O)_2(CH=CH_2)$, $-NR_{12}C(=O)CH_2Br$, -

$NR_{12}C(=O)CH_2I$, $-NHC(=O)CH_2Br$, $-NHC(=O)CH_2I$, $-ONH_2$, ,

, , or


;



10 R^{10} is



each R^{11} is independently selected from C_1-C_6 alkyl;

each R^{12} is independently selected from H and C_1-C_6 alkyl;

R^{13} is , or $-LR^9$;

each R^{14} is independently selected from H and C_1-C_6 alkyl;


15


X_3 is  or ;


each m is independently selected from 1, 2, 3, 4, 5, and 6;

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.


17. The compound of any one of claims 1 to 5, or 15 to 16, wherein R^4 is $-L_1R^9$, -




18. The compound of any one of claims 1 to 5, or 15 to 17 wherein R^{13} is , ,



5 19. The compound of any one of claims 1 to 18, wherein R^9 is




20. The compound of any one of claims 1 to 19, wherein R^9 is



21. The compound of any one of claims 1 to 20, wherein L is $-L_1$ - and $-L_1$ - is selected from:


$-(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_m-$, $-(CH_2)_m-$, $-(CH_2)_mC(=O)X_2X_1C(=O)-$, $-C(=O)X_1X_2C(=O)(CH_2)_m-$, $-(CH_2)_m(O(CH_2)_m)_nC(=O)-$, $-C(=O)((CH_2)_mO)_n(CH_2)_m-$,



, $-(CH_2)_m(O(CH_2)_m)_nS(=O)_2(CH_2)_m-$, $-(CH_2)_mS(=O)_2((CH_2)_mO)_n(CH_2)_m-$, $-(CH_2)_mNH(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mNH(CH_2)_m-$,
 5 $-(CH_2)_mNR^{12}(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mNR^{12}(CH_2)_m-$, $-(CH_2)_mS(=O)_2-$, $-S(=O)_2(CH_2)_m-$, $-(CH_2)_mX_3(CH_2)_m-$, $-(CH_2)_mX_3(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mX_3(CH_2)_m-$, $-(CH_2)_mNHC(=O)-$, $-C(=O)NH(CH_2)_m-$, $-(CH_2)_mX_3(CH_2)_m(O(CH_2)_m)_nC(=O)-$, $-C(=O)((CH_2)_mO)_n(CH_2)_mX_3(CH_2)_m-$, $-(CH_2)_mC(=O)NH(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mNHC(=O)(CH_2)_m-$, $-NR_{12}S(=O)_2(CH_2)_mX_3(CH_2)_m-$, and $-(CH_2)_mX_3(CH_2)_mS(=O)_2NR_{12}-$.

22. The compound of any one of claims 1 to 21, wherein L is $-L_1-$ and $-L_1-$ is selected from:

$-(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_m-$, $-(CH_2)_m-$, $-(CH_2)_mC(=O)X_2X_1C(=O)-$, $-C(=O)X_1X_2C(=O)(CH_2)_m-$, $-(CH_2)_m(O(CH_2)_m)_nC(=O)-$, $-C(=O)((CH_2)_mO)_n(CH_2)_m-$,



, $-(CH_2)_m(O(CH_2)_m)_nS(=O)_2(CH_2)_m-$, $-(CH_2)_mS(=O)_2((CH_2)_mO)_n(CH_2)_m-$, $-(CH_2)_mNH(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mNH(CH_2)_m-$,
 15 $-(CH_2)_mNR^{12}(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mNR^{12}(CH_2)_m-$, $-(CH_2)_mS(=O)_2-$, and $-S(=O)_2(CH_2)_m-$.


23. The compound of any one of claims 1 to 4, wherein:

20 R^1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C_1-C_2 alkylene bridge, or R^1 is a C-linked 5-8 membered fused bicyclic heterocycloalkyl containing 1-2 N heteroatoms, wherein

said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is unsubstituted,

or said C-linked 6 membered heterocycloalkyl or said C-linked 5-8 membered fused bicyclic heterocycloalkyl is substituted with 1 to 3 substituents independently selected from R^5 ;

R^2 is $-C_1-C_6$ alkyl;




R^5 is C_1 - C_6 alkyl, -C(=O)R¹¹, -(CH₂)_mOH, -C(=O)(CH₂)_mOH, -C(=O)((CH₂)_mO)_nR¹², or C_1 - C_6 alkyl substituted with -CN, or -C(=O)NH₂;

5 R^8 is H;

each R^{11} is independently selected from C_1 - C_6 alkyl;

each R^{12} is independently selected from H and C_1 - C_6 alkyl;

R^{13} is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with phenyl,



10 R^{19} is H or C_1 - C_6 alkyl;


each m is independently selected from 1, 2, 3, 4, 5, and 6;


each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.


24. The compound of claim 23, wherein:

R^1 is a C-linked 6 membered heterocycloalkyl containing 1-2 N heteroatoms and a C_1 - C_2 alkylene bridge, wherein the C-linked 6 membered heterocycloalkyl is unsubstituted or the C-linked 6 membered heterocycloalkyl is substituted with 1 to 3 substituents independently selected from R^5 .



25. The compound of any one of claims 1 to 14, or 23 to 24, wherein R^4 is -OH, -OCH₃, -




20 26. The compound of any one of claims 1, 5 to 16, or 19 to 24, wherein R^{13} is  ,




27. The compound of any one of claims 1 to 5 or claims 13 to 26, wherein R¹ is




28. The compound of any one of claims 1 to 5 or claims 13 to 26, wherein R¹



5 29. The compound of any one of claims 1 to 5, 13, 23, or 25 to 26, wherein R¹



30. The compound of any one of claims 1 to 5, 13, 23, or 25 to 26, wherein R¹ is




31. The compound of any one of claims 1 to 30, wherein R⁵ is -CH₃ or -C(=O)CH₃.


10 32. The compound of any one of claims 1 to 31, wherein R¹² is H, -CH₃ or -CH₂CH₃.

33. The compound of any one of claims 1 to 32, wherein R² is methyl, ethyl, isopropyl or sec-butyl.


34. The compound of any one of claims 1 to 5, wherein:



15 R² is methyl, ethyl, isopropyl or sec-butyl;



R⁴ is -OH;











L is L_1 , wherein L_1 is selected from $-(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_m-$, -





$(CH_2)_m(O(CH_2)_m)_nC(=O)-$, and $-C(=O)((CH_2)_mO)_n(CH_2)_m-$;

each m is independently selected from 1, 2, 3, 4, 5, and 6;





5 each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.






35. The compound of claim 1 selected from,












5












5











5



















5
















5










5

10








5











10



5




10




5

10



36. An immunoconjugate of Formula (II):



Formula (II)





wherein:

Ab represents an antigen binding moiety;

L is selected from $-L_1L_2-$, and $-L_1$,

wherein

L_1 is selected from $-(CH_2)_m-$, $-C(=O)(CH_2)_m-$, $-C(=O)X_1X_2C(=O)(CH_2)_m-$,
 $C(=O)((CH_2)_mO)_n(CH_2)_m-$, $-(CH_2)_mS(=O)_2((CH_2)_mO)_n(CH_2)_m-$,
 $C(=O)(CH_2)_mNR^{12}(CH_2)_m-$, $-C(=O)(CH_2)_mX_3((CH_2)_mO)_n-$, $-(CH_2)_mC(=O)-$,
 $(CH_2)_mC(=O)X_2X_1C(=O)-$, $-(CH_2)_m(O(CH_2)_m)_nC(=O)-$,
 5 $(CH_2)_m(O(CH_2)_m)_nS(=O)_2(CH_2)_m-$, $-(CH_2)_mNR^{12}(CH_2)_mC(=O)-$,
 $(CH_2)_mX_3(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mX_3(CH_2)_m-$,
 $(CH_2)_mX_3(CH_2)_m(O(CH_2)_m)_nC(=O)-$, $-C(=O)((CH_2)_mO)_n(CH_2)_mX_3(CH_2)_m-$,
 $(CH_2)_mC(=O)NR^{12}(CH_2)_mC(=O)-$, $-C(=O)(CH_2)_mNR^{12}C(=O)(CH_2)_m-$,
 $C(=O)(CH_2)_mNR^{12}C(=O)O(CH_2)_m-$, $-(CH_2)_mOC(=O)NR^{12}(CH_2)_mC(=O)-$,
 10 $NR^{12}((CH_2)_mO)_n(CH_2)_mX_3(CH_2)_m-$, $-(CH_2)_mX_3(CH_2)_m(O(CH_2)_m)_nNR^{12}-$,
 $NR^{12}C(=O)(CH_2)_m-$, $-(CH_2)_mC(=O)NR^{12}-$, $-(CH_2)_mX_3(CH_2)_m-$, $-C(=O)NR^{12}(CH_2)_m-$,
 $-(CH_2)_mNR^{12}C(=O)-$, $-NR^{12}((CH_2)_mO)_n(CH_2)_m-$, $-(CH_2)_m(O(CH_2)_m)_nNR^{12}-$,
 $S(=O)_2(CH_2)_m-$, $-(CH_2)_mS(=O)_2-$, $-S-$, $-NR_{12}S(=O)_2(CH_2)_mX_3(CH_2)_m-$,



and L_2 is independently selected from a bond and L_1 ;
 y is an integer from 1 to 16;


R¹⁰¹ is a 6 membered heterocycloalkyl divalent radical containing 1-2 N heteroatoms and a C₁-C₂alkylene bridge, wherein the 6 membered heterocycloalkyl divalent

radical is C-linked to the  group and is N-linked to L₁ or is C-linked to L₁, and the 6 membered heterocycloalkyl divalent radical is unsubstituted or the 6 membered heterocycloalkyl divalent radical is substituted with 1 to 3 substituents independently selected from R⁵;

or R¹⁰¹ is a 5-8 membered fused bicyclic heterocycloalkyl divalent radical containing 1-2 N heteroatoms, wherein the 5-8 membered fused bicyclic

heterocycloalkyl divalent radical is C-linked to the  group and is N-linked to L₁ or is C-linked to L₁, and the 5-8 membered fused bicyclic heterocycloalkyl divalent radical is unsubstituted or the 5-8 membered fused bicyclic heterocycloalkyl divalent radical is substituted with 1 to 3 substituents independently selected from R⁵;

R² is -C₁-C₆alkyl;




R⁴ is -OH, C₁-C₆alkoxy, or -NHS(O)₂R₁₁;

R⁵ is C₁-C₆alkyl, -C(=O)R¹¹, -(CH₂)_mOH, -C(=O)(CH₂)_mOH, -C(=O)((CH₂)_mO)_nR¹², or C₁-C₆alkyl substituted with -CN, or -C(=O)NH₂;

R¹¹ is C₁-C₆alkyl;

each R¹² is independently selected from H and C₁-C₆alkyl;

R¹³ is tetrazolyl, imidazolyl substituted with phenyl, oxadiazolyl substituted with



R¹⁹ is H or C₁-C₆alkyl;

each m is independently selected from 1, 2, 3, 4, 5, and 6;

and

each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.

37. The immunoconjugate of claim 36, wherein the immunoconjugate of Formula (II) is an immunoconjugate of Formula (IIb):



5





10

heterocycloalkyl divalent radical is C-linked to the  group and is N-linked to L₁, and the 6 membered heterocycloalkyl divalent radical is unsubstituted or the 6 membered heterocycloalkyl divalent radical is substituted with 1 to 3 substituents independently selected from R⁵;

R¹⁰¹ is a 5-8 membered fused bicyclic heterocycloalkyl divalent radical containing 1-2 N heteroatoms, wherein the 5-8 membered fused bicyclic heterocycloalkyl

20


42. The immunoconjugate of any one of claims 36 to 41, wherein R³ is



43. The immunoconjugate of any one of claims 36 to 42, wherein:

R⁴ is -OH, or C₁-C₆alkoxy.

44. The immunoconjugate of any one of claims 36 to 42, wherein:



45. The immunoconjugate of any one of claims 36 to 43, wherein R⁴ is -OH.

46. The immunoconjugate of any one of claims 36 to 45, wherein R⁵ is -CH₃ or -C(=O)CH₃.


47. The immunoconjugate of any one of claims 36 to 46, wherein R¹² is H, -CH₃ or -CH₂CH₃.

48. The immunoconjugate of any one of claims 36 to 47, wherein R² is methyl, ethyl, isopropyl or sec-butyl.

49. The immunoconjugate of any one of claims 36 to 48, wherein:

L₁ is -(CH₂)_mC(=O)*-, -(CH₂)_m-, -(CH₂)_mC(=O)X₂X₁C(=O)*-, -
 (CH₂)_m(O(CH₂)_m)_nC(=O)*-, -(CH₂)_m(O(CH₂)_m)_nS(=O)₂(CH₂)_m*-, -
 (CH₂)_mNR¹²(CH₂)_mC(=O)*-, -((CH₂)_mO)_n(CH₂)_m*-, -(CH₂)_mX₃(CH₂)_mC(=O)*-, -
 (CH₂)_mX₃(CH₂)_m-, -(CH₂)_mX₃(CH₂)_m(O(CH₂)_m)_nC(=O)*-, -
 (CH₂)_mC(=O)NH(CH₂)_mC(=O)*-, -(CH₂)_mS(=O)₂*-, or -
 (CH₂)_mOC(=O)NH(CH₂)_mC(=O)*-, and wherein the * indicates the point of attachment to R¹⁰¹;


and



50. The immunoconjugate of any one of claims 36 to 49, wherein:

L_1 is selected from $-(CH_2)_mC(=O)^*$ -, $-(CH_2)_mX_3(CH_2)_mC(=O)^*$ -, $-(CH_2)_m$ -, $-(CH_2)_mX_3(CH_2)_m$ -, $-(CH_2)_mC(=O)X_2X_1C(=O)^*$ -, $-(CH_2)_m(O(CH_2)_m)_nC(=O)^*$ -, $-(CH_2)_mX_3(CH_2)_m(O(CH_2)_m)_nC(=O)^*$ -, $-(CH_2)_m(O(CH_2)_m)_nS(=O)_2(CH_2)_m$ - and $-(CH_2)_mNR^{12}(CH_2)_mC(=O)^*$ -, wherein the * indicates the point of attachment to R^{101} ;


and



51. The immunoconjugate of any one of claims 36 to 50, wherein:

L_1 is selected from $-(CH_2)_mC(=O)^*$ -, $-(CH_2)_m$ -, $-(CH_2)_mX_3(CH_2)_mC(=O)^*$ -, $-(CH_2)_mC(=O)X_2X_1C(=O)^*$ -, $-(CH_2)_mX_3(CH_2)_m$ -, $-(CH_2)_m(O(CH_2)_m)_nC(=O)^*$ -, $-(CH_2)_mX_3(CH_2)_m(O(CH_2)_m)_nC(=O)^*$ -, $-(CH_2)_m(O(CH_2)_m)_nS(=O)_2(CH_2)_m$ - and $-(CH_2)_mNR^{12}(CH_2)_mC(=O)^*$ -, wherein the * indicates the point of attachment to R^{101} ;

and



52. A pharmaceutical composition comprising an immunoconjugate of any one of claims 36 to 51, and one or more pharmaceutically acceptable carriers.

53. A combination comprising a therapeutically effective amount of an immunoconjugate of any one of claims 36 to 51, and one or more therapeutically active co-agents.